TGR-1202 (Umbralisib) in Treatment Naïve Patients With Chronic Lymphocytic Leukemia (CLL)
Status:
Recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see how safe and effective the investigational drug
umbralisib (TGR-1202) is in individuals with Chronic Lymphocytic Leukemia (CLL)
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute